Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Demeetra logo — Cell Line Development from Edit to Expression

Demeetra

Cell Line Development from Edit to Expression

Founded 2019 United States Lexington, United States 17 employees Agriculture, Biotechnology +2

General Information

Company Name Demeetra
Founded Year 2019
Location United States Lexington, United States
Employees 17
Industries Agriculture, Biotechnology, Pharmaceutical +1
Social

BounceWatch is an independent company data service, not affiliated with Demeetra. To contact Demeetra, visit demeetra.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Demeetra compare?

A PDF of Demeetra and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Demeetra soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Pricing Changed Oct 16, 2026

Demeetra removed a plan priced at $30,000 per year and added the Evaluation plan for $5,000.

Get alerts when Demeetra shows new signals

About Demeetra

Demeetra empowers biomanufacturers and researchers to move rapidly from precise gene edits to high-yield expression using a suite of proprietary, commercially accessible technologies. Our solutions optimize cell line development while eliminating common licensing and scalability barriers. Our Technologies: • Cas-CLOVER™: A high-fidelity nuclease that delivers clean, efficient gene knockouts and targeted knock-ins, with performance that rivals or exceeds CRISPR/Cas9. • Harbor-IN™: A license-free transposase that enables stable integration of large genetic payloads, achieving high titers without royalties or downstream fees. • CleanCut™ Host Cell Portfolio: Features a suspension CHO GS knockout line and an expanding collection of pre-engineered cell lines optimized for productivity and feature flexibility, accelerating your path to milestone success. Why Demeetra: • Editing Efficiency Meets Business Clarity: From superior editing precision to simplified licensing models, we remove the barriers that slow scientific and commercial progress. • Clear Freedom to Operate: Straightforward licensing backed by issued patents and strategic foundational CRISPR/Cas9 agreements. • No Royalties or Milestone Fees: Keep your autonomy with zero downstream restrictions or sublicensing complications. • Enhanced Performance: Achieve larger knock-ins, higher expression yields, and cleaner edits than traditional Cas9 or other transposase systems. Whether you’re advancing research or scaling a biotherapeutic pipeline, Demeetra equips your team with the tools and freedom to move forward faster and with confidence.

Pricing

as listed on Nov 1, 2026

$1,500–75,000 one-time

  • 1 vial, 25 µg: $1,500 one-time
  • 2 vials, 25 µg each: $2,700 one-time
  • 3 vials, 25 µg each: $2,975 one-time
  • 5 vials, 25 µg each: $6,375 one-time
Demeetra's pricing page

No funding data available for Demeetra yet.

FAQ About Demeetra

Cell Line Development from Edit to Expression
Demeetra was founded in 2019.
Demeetra is headquartered in Lexington, United States.
Demeetra operates in Agriculture, Biotechnology, Pharmaceutical and Marketing.
As listed on Demeetra's pricing page on Nov 1, 2026: $1,500–75,000 one-time (1 vial, 25 µg: $1,500 one-time; 2 vials, 25 µg each: $2,700 one-time; 3 vials, 25 µg each: $2,975 one-time; 5 vials, 25 µg each: $6,375 one-time).
Demeetra has approximately 17 employees.

We're actively collecting intelligence on Demeetra.

Source: BounceWatch company record for Demeetra, https://bouncewatch.com/company/demeetra, updated 28 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes